Free tool
FAERS Monitor: Diovan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021283 or its brand name (Diovan, Valsartan). Reports on generic versions are filed under their own applications.
Reports
105,697
Serious
80,579
76% of reports
Hospitalization
39,667
Death reported
9,601
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective6,427
- fatigue5,691
- dizziness5,453
- dyspnoea5,406
- nausea5,312
- diarrhoea4,778
- headache4,671
- hypertension4,393
- blood pressure increased4,307
- pain3,901
- fall3,690
- asthenia3,686
- malaise3,654
- acute kidney injury3,314
- off label use3,168
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,626 |
| 2005 | 2,193 |
| 2006 | 2,550 |
| 2007 | 2,616 |
| 2008 | 2,697 |
| 2009 | 3,818 |
| 2010 | 4,607 |
| 2011 | 5,852 |
| 2012 | 5,748 |
| 2013 | 4,926 |
| 2014 | 5,417 |
| 2015 | 6,320 |
| 2016 | 6,084 |
| 2017 | 5,890 |
| 2018 | 8,380 |
| 2019 | 6,939 |
| 2020 | 5,330 |
| 2021 | 4,715 |
| 2022 | 4,408 |
| 2023 | 3,921 |
| 2024 | 4,235 |
| 2025 | 4,198 |
| 2026 | 3,216 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,948,462 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood pressure increasedSignal | 4,307 | 5.7 | 5.6 | 16,496 |
| acute kidney injurySignal | 3,314 | 4.4 | 4.2 | 8,523 |
| hypertensionSignal | 4,393 | 4.2 | 4.1 | 10,566 |
| fallSignal | 3,690 | 2.2 | 2.2 | 2,484 |
| dizzinessSignal | 5,453 | 2.2 | 2.1 | 3,565 |
| asthenia | 3,686 | 2.0 | 1.9 | 1,747 |
| dyspnoea | 5,406 | 1.9 | 1.9 | 2,381 |
| malaise | 3,654 | 1.7 | 1.6 | 978 |
| headache | 4,671 | 1.5 | 1.4 | 759 |
| diarrhoea | 4,778 | 1.5 | 1.4 | 752 |
| fatigue | 5,691 | 1.5 | 1.4 | 843 |
| nausea | 5,312 | 1.3 | 1.3 | 467 |
| pain | 3,901 | 1.3 | 1.2 | 222 |
| drug ineffective | 6,427 | 1.0 | 0.9 | 6 |
| off label use | 3,168 | 0.7 | 0.7 | 362 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.